allantopyrone A: from an endophytic fungus, Allantophomopsis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 46704283 |
| MeSH ID | M0547343 |
| Synonym |
|---|
| allantopyrone a |
Allantopyrone A is a fungal metabolite that uniquely possesses two α,β-unsaturated carbonyl moieties. It was originally isolated from the endophytic fungus Allantophomopsis lycopodina KS-97.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Allantopyrone A is an α-pyrone metabolite that was originally isolated from the endophytic fungus Allantophomopsis lycopodina KS-97. " | ( Allantopyrone A interferes with the degradation of hypoxia-inducible factor 1α protein by reducing proteasome activity in human fibrosarcoma HT-1080 cells. Kataoka, T; Kawaguchi, K; Kimura, KI; Muroi, M; Okuda, C; Osada, H; Sanada, E; Shiono, Y; Takeda, K; Ueda, Y, 2023) | 3.8 |
| "Allantopyrone A is a fungal metabolite that uniquely possesses two α,β-unsaturated carbonyl moieties. " | ( Allantopyrone A interferes with multiple components of the TNF receptor 1 complex and blocks RIP1 modifications in the TNF-α-induced signaling pathway. Hirano, S; Kataoka, T; Kimura, KI; Niwa, M; Quach, HT; Shiono, Y; Tanigaki, R; Yamada, Y; Yokoigawa, J, 2017) | 3.34 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Allantopyrone A did not inhibit the prolyl hydroxylation of HIF-1α, but enhanced the ubiquitination of cellular proteins." | ( Allantopyrone A interferes with the degradation of hypoxia-inducible factor 1α protein by reducing proteasome activity in human fibrosarcoma HT-1080 cells. Kataoka, T; Kawaguchi, K; Kimura, KI; Muroi, M; Okuda, C; Osada, H; Sanada, E; Shiono, Y; Takeda, K; Ueda, Y, 2023) | 3.07 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.20) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||